• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

Dexamethasone effective as initial therapy for immune thrombocytopenic purpura [Classics Series]

byAndrew Cheung, MD MBA
July 18, 2014
in Emergency Classics, General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Of 125 patients with newly diagnosed immune thrombocytopenic purpura, 106 (85%) had an initial response to high-dose dexamethasone therapy

2. Half of the 106 patients with an initial response to high-dose dexamethasone had a sustained response after six months of follow-up

Original Date of Publication: August 28, 2003

Study Rundown: This study assessed the effectiveness of high-dose dexamethasone as an initial therapy for newly diagnosed immune thrombocytopenic purpura (ITP). The results were promising as 85% of patients showed an initial response to therapy and half of these patients had a sustained response after six months of follow-up. This demonstrated that a short course (four days) of high dose glucocorticoid could be effective as an initial treatment for ITP, avoiding the numerous and potentially severe complications associated with longer courses of prednisone, which was the standard therapy. The high-dose dexamethasone was well-tolerated. No patients discontinued treatment due to side effects in this study. This prospective case series involved a relatively large sample of patients; however, the study lacked a control group to compare its performance to a placebo or treatment with prednisone.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

In-Depth [case series study]: This study recruited consecutive adult patients who presented with a new diagnosis of ITP. Of 157 consecutive patients, 125 met eligibility criteria – a platelet count of less than 20,000 per mm3, or a platelet count of less than 50,000 per mm3  and clinically significant bleeding. The exclusion criteria were relapsed ITP, treatment with corticosteroids in the previous 6 months, a history of clinically significant adverse effects from previous corticosteroid treatment (e.g., psychosis, avascular necrosis), uncontrolled hypertension or diabetes mellitus, and pregnancy. Patients were treated with 40 mg daily of oral dexamethasone for four days. Initial treatment response was defined as an increase in platelet count of at least 30,000 per mm3, a platelet count greater than 50,000 mm3 by day 10 after treatment was started, and bleeding cessation. A sustained response was defined as a platelet count above 50,000 per mm3 after six months of follow-up.

RELATED REPORTS

Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

Of the 125 patients included, 106 (85%) had an initial response to high-dose dexamethasone. Of the 19 patients who did not have a treatment response, 14 responded to either intravenous immune globulin or anti-D immune globulin. The remaining patients underwent splenectomy or received cytotoxic therapy. The median follow-up period was 30.5 months. Of the 106 patients with an initial response to dexamethasone therapy, 53 (50%) had a sustained response and required no further treatment. The remaining 53 patients had a relapse but responded to a second course of high-dose dexamethasone. No patient discontinued treatment due to adverse effects.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: dexamethasoneITP
Previous Post

Risk of delayed-onset ulnar neuritis after arthroscopic release of elbow contracture

Next Post

Proposed need for regulation of direct-to-consumer genetic testing

RelatedReports

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer

September 12, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

July 16, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

July 7, 2022
#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
Next Post
BRAF V600E mutations linked with increased mortality in thyroid cancer

Proposed need for regulation of direct-to-consumer genetic testing

Mortality after trauma increasingly due to preexisting conditions

Analysis identifies radiology workflow bottlenecks in massive casualty incident

Retinopathy of prematurity associated with nonvisual impairment in childhood

Functional decline in children with retinoblastoma greater than expected

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
  • Machine renal perfusion reduces delayed graft function after transplantation
  • COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options